CN117202936A - 胰高血糖素样肽化合物 - Google Patents

胰高血糖素样肽化合物 Download PDF

Info

Publication number
CN117202936A
CN117202936A CN202280029619.8A CN202280029619A CN117202936A CN 117202936 A CN117202936 A CN 117202936A CN 202280029619 A CN202280029619 A CN 202280029619A CN 117202936 A CN117202936 A CN 117202936A
Authority
CN
China
Prior art keywords
compound
formula
pharmaceutically acceptable
acceptable salt
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280029619.8A
Other languages
English (en)
Chinese (zh)
Inventor
V·博利厄
K·加利安
J·高
C·金斯伯格-莫拉夫
P·贾因
J·马尔辛克维西恩
W·迈克尔
茂木宗人
M·马罗
S·帕特尔
S·普拉默
A·辛格
A·尤塞拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN117202936A publication Critical patent/CN117202936A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202280029619.8A 2021-04-21 2022-04-20 胰高血糖素样肽化合物 Pending CN117202936A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21169757 2021-04-21
EP21169757.8 2021-04-21
PCT/IB2022/053698 WO2022224164A1 (en) 2021-04-21 2022-04-20 Glucagon like peptide compounds

Publications (1)

Publication Number Publication Date
CN117202936A true CN117202936A (zh) 2023-12-08

Family

ID=75639721

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280029619.8A Pending CN117202936A (zh) 2021-04-21 2022-04-20 胰高血糖素样肽化合物

Country Status (14)

Country Link
US (1) US20240247042A1 (https=)
EP (1) EP4326330A1 (https=)
JP (1) JP2024514352A (https=)
KR (1) KR20230171471A (https=)
CN (1) CN117202936A (https=)
AR (1) AR125400A1 (https=)
AU (1) AU2022260805A1 (https=)
BR (1) BR112023021597A2 (https=)
CA (1) CA3216058A1 (https=)
CL (1) CL2023003091A1 (https=)
IL (1) IL307822A (https=)
MX (1) MX2023012290A (https=)
TW (1) TW202304500A (https=)
WO (1) WO2022224164A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4048664A1 (en) 2019-10-25 2022-08-31 Gilead Sciences, Inc. Glp-1r modulating compounds
EP4247804A1 (en) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
IL306110A (en) 2021-04-21 2023-11-01 Gilead Sciences Inc Carboxy-benzimidazole glp-1r modulating compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
JP6730278B2 (ja) * 2014-11-27 2020-07-29 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
MA41580A (fr) * 2015-01-23 2017-11-29 Novartis Ag Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée

Also Published As

Publication number Publication date
EP4326330A1 (en) 2024-02-28
IL307822A (en) 2023-12-01
CL2023003091A1 (es) 2024-05-03
WO2022224164A1 (en) 2022-10-27
CA3216058A1 (en) 2022-10-27
TW202304500A (zh) 2023-02-01
JP2024514352A (ja) 2024-04-01
AR125400A1 (es) 2023-07-12
BR112023021597A2 (pt) 2024-02-06
MX2023012290A (es) 2023-10-26
KR20230171471A (ko) 2023-12-20
US20240247042A1 (en) 2024-07-25
AU2022260805A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
CN104470948B (zh) Gip-glp-1双激动剂化合物及方法
CN117202936A (zh) 胰高血糖素样肽化合物
JP2023100722A (ja) タンパク質分解安定性が改善された新規ポリペプチド並びにその調製方法及び使用方法
TW202140528A (zh) Gip/glp1共促效劑化合物
EP2413955A2 (en) N-terminus conformationally constrained glp-1 receptor agonist compounds
US20230142095A1 (en) Long-Acting Adrenomedullin Derivative
CN113423691A (zh) 肽结合剂
TW201105327A (en) Modulators of metabolism and the treatment of disorders related thereto
JP7812338B2 (ja) Ｇｌｐ受容体アゴニスト
CN115594752A (zh) 一种长效双激动剂化合物
JP2025102922A (ja) 新規ｌｒｐ１結合ペプチド
US20240408218A1 (en) Conjugates of glucagon and ampk activators
EP3665182A1 (en) Novel compounds activating the nrf2 pathway
WO2026052063A1 (en) Glp-1 polypeptide prodrugs and uses thereof
US20240270809A1 (en) Oral glp receptor agonists
RU2838225C1 (ru) Агонисты рецепторов glp
RU2836443C1 (ru) Пероральные агонисты рецепторов glp
EP4323354B1 (en) 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
RU2808687C2 (ru) Связывающее вещество для пептидов
WO2026082119A1 (zh) 一种多肽化合物及其应用
AU2024377281A1 (en) Triple agonist compound
AU2024376300A1 (en) Tri-agonist compound
CN118715220A (zh) 2-((4-((s)-2-(4-氯-2-氟苯基)-2-甲基苯并[d][1,3]二氧戊环-4-基)哌啶-1-基)甲基)-1-(((s)-氧杂环丁烷-2-基)甲基)-1h-咪唑衍生物作为glp1受体激活剂用于治疗肥胖症
AU2024374868A1 (en) Dual agonist compound
WO2026067828A1 (zh) Glp-1/gip受体双重激动的多肽化合物、其制备方法及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination